Aс/Bi generator for direct synthesis of Bi-labeled bioconjugates.

Background: Bi is a short-lived radionuclide currently trialed for alpha therapy of various oncological diseases. A serious obstacle to the wide medical use is decay losses of Bi during a conventional synthesis of radiopharmaceuticals. In this work, we aimed to develop a two-column Aс/Bi generator providing the accumulation of Bi separately from the parent Ac via continuous circular separation and decay of intermediate Fr.

DTPA(DOTA)-Nimotuzumab Radiolabeling with Generator-produced Thorium for Radioimmunotherapy of EGFR-overexpressing Carcinomas.

Introduction: The feasibility of preparing the "in-house" generators and the Th- DTPA(DOTA)-Nimotuzumab radioimmunoconjugate was evaluated. Th is perspective for TAT, however, due to short half-life it is preferable to apply this radionuclide for readily available epithelial malignancies. Nimotuzumab being specific for EGFR expressing cells as a targeting moiety is considered to be suitable for thorium delivery.